# Lingo Manufacturer: [Abbott](/companies/abbott) Category: biometric ## Summary Abbott's Lingo is an over-the-counter continuous glucose monitor for non-diabetic and wellness consumers, built on Abbott's FreeStyle Libre sensor platform (FDA 510(k) K233655, decided May 29, 2024; Class II integrated CGM): a disposable biosensor worn up to 14 days on the back of the upper arm. It is the adaptive-algorithmic end of the glucose cell, the documented contrast to Stelo's generative AI: the app's 'Lingo Count' daily glucose-spike metric with adaptive targets, food and activity logging, and rule-based personalized recommendations are adaptive-algorithmic, not generative. 'Lingo Live' is free roughly 30-minute sessions with human Abbott nutritionists, not an AI coach, and DEPLOY surfaces that distinction prominently. Pricing starts at about $54 for a 2-week single-biosensor plan, with recurring biweekly and monthly multi-sensor tiers. From Abbott (NYSE: ABT). Cap-flag: the cleared indication is adults 18+ not on insulin, explicitly NOT for diagnosis of any disease including diabetes. ## Top line > Lingo is shipping now at $54 (actual sale price), no capability claims are on file, the model has no verified field deployments in the registry, and no incidents are on record. ## Readiness - **Availability** (shipping-now): Shipping now. - **Price honesty** (actual-sale-price): One price on file: $54 (actual sale price). - **Capability honesty** (no-claims): No reviewed capability claims on file for Lingo. - **Real-world use** (commercial): Maturity: commercial. No verified deployments in the registry. - **Safety record** (no-incidents): No incidents on record. No verified deployments either. ## What it claims to do _No reviewed capability claims on file._ ## Price - $54, _actual-sale-price_ ([Abbott (Lingo)](https://www.hellolingo.com/)) _as of 2024-06-10_ ## Real-world use _No verified deployments on file for Lingo._ ## Safety record _No incidents on record. No verified deployments either, so the absence is uninformative._ ## Privacy _No privacy practices disclosed or on file for Lingo._ ## Specs - **notes**: [{"label":"Boundary INCLUDE (narrow) - glucose-biometric + adaptive insight layer","value":"Glucose is in the biometric definition; Lingo is biometric-primary (interstitial glucose). It clears the medical-sensor-without-meaningful-AI exclusion bar on INSIGHT-LAYER substance: Lingo Count with adaptive targets, algorithm-driven personalized food-response recommendations, and Challenges are the differentiator vs a bare CGM graph (which Abbott deliberately does not sell to this wellness audience). Would it exist without the insight layer? Yes-and-meaningfully-degraded -> above the thin-AI floor. Second example of the GLUCOSE cell alongside Stelo."},{"label":"Cap-flag: NOT at Stelo parity (AI is adaptive/algorithmic, NOT verified generative)","value":"Critical distinction: Dexcom Stelo cleared the bar with a GENUINE generative-AI layer (Google Cloud Vertex AI + Gemini Weekly Insights). Lingo's primary sources describe adaptive / rule-based personalization only - no documented generative-AI layer, no 'Lingo Coach' AI agent (coaching is algorithmic plus human nutritionist via Lingo Live). Do NOT grant Lingo Stelo-equivalent AI standing. It passes on insight-layer substance, not on generative-AI grounds; this is the borderline case of the cohort and is flagged as such."},{"label":"FDA anchor","value":"FDA 510(k) K233655 decided May 29 2024; OTC integrated CGM; adults 18+ not on insulin; explicitly not for diagnosis of any disease. Directly parallel to Stelo's OTC posture (Stelo = De Novo Mar 2024). Cleared via 510(k) (Stelo via De Novo) - both are OTC wellness clearances."},{"label":"Claimed but NOT verified","value":"Any AI comparable to Stelo's generative AI (not verified - adaptive/rule-based only); a named 'Lingo Coach' AI agent (does not exist); exact stale tier table ($49/$89 figures - verified entry is ~$54/2-week, time-sensitive); any generative-AI roadmap for Lingo (none announced, unlike Dexcom)."}] - **specs**: Lingo: over-the-counter continuous glucose monitor (CGM) biosensor for non-diabetic / wellness consumers, built on Abbott's FreeStyle Libre sensor platform. Disposable biosensor worn on the back of the upper arm, up to 14-day wear, glucose-oxidase amperometric assay. FDA 510(k) K233655 decided May 29 2024 (announced Jun 10 2024); Class II integrated CGM (21 CFR 862.1355); indication: adults 18+ NOT on insulin; explicitly NOT for diagnosis of any disease including diabetes. App: real-time glucose graph, 'Lingo Count' daily glucose-spike metric with adaptive targets, food/activity logging, algorithm-driven personalized recommendations, 'Lingo Challenges' behavioral nudges, and 'Lingo Live' (free ~30-min sessions with human Abbott nutritionists). Pricing: entry ~$54 for a 2-week single-biosensor starter plan, recurring biweekly/monthly multi-sensor tiers. Maker: Abbott (NYSE: ABT), Abbott Diabetes Care. - **formFactor**: biometric (biometric-primary GLUCOSE biosensor / OTC continuous glucose monitor + adaptive insight layer; second glucose example alongside Stelo) ## What's under the hood _No brain on file for Lingo._ ## Frequently asked questions ### Is the Lingo actually available for purchase? Yes, shipping now. _Source: [Abbott receives FDA clearance for two OTC CGM systems (Lingo + Libre Rio; FDA 510(k) K233655 decided May 29 2024; adults 18+ not on insulin)](https://abbott.mediaroom.com/2024-06-10-Abbott-Receives-FDA-Clearance-for-Two-Over-the-Counter-Continuous-Glucose-Monitoring-Systems)._ ### What does the Lingo cost? Lingo costs $54 one-time (actual sale price). _Source: [Abbott (Lingo)](https://www.hellolingo.com/)._ ### Where is the Lingo being used? No verified field deployments on record. ### Is the Lingo safe? No incidents on record, but with no verified field deployments either, the absence is uninformative. ### How does the Lingo handle privacy? No privacy practices disclosed or on file for Lingo. ### Who makes the Lingo? Lingo is made by Abbott, based in Abbott Park, Illinois, USA. _Source: [Abbott receives FDA clearance for two OTC CGM systems (Lingo + Libre Rio; FDA 510(k) K233655 decided May 29 2024; adults 18+ not on insulin)](https://abbott.mediaroom.com/2024-06-10-Abbott-Receives-FDA-Clearance-for-Two-Over-the-Counter-Continuous-Glucose-Monitoring-Systems)._ ## Manufacturer - [Abbott (https://abbott.mediaroom.com/2024-06-10-Abbott-Receives-FDA-Clearance-for-Two-Over-the-Counter-Continuous-Glucose-Monitoring-Systems)](https://abbott.mediaroom.com/2024-06-10-Abbott-Receives-FDA-Clearance-for-Two-Over-the-Counter-Continuous-Glucose-Monitoring-Systems) ## Compared to - [Ultrahuman Ring (Air / Pro)](/consumer/models/ultrahuman-ring-air) - [Stelo](/consumer/models/stelo) - [Withings ScanWatch](/consumer/models/withings-scanwatch) ## Sources 1. [Abbott receives FDA clearance for two OTC CGM systems (Lingo + Libre Rio; FDA 510(k) K233655 decided May 29 2024; adults 18+ not on insulin)](https://abbott.mediaroom.com/2024-06-10-Abbott-Receives-FDA-Clearance-for-Two-Over-the-Counter-Continuous-Glucose-Monitoring-Systems) 2. [FDA 510(k) K233655: OTC integrated continuous glucose monitoring system (Class II, 21 CFR 862.1355; adults 18+ not on insulin; not for diagnosis of any disease)](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=K233655) 3. [Lingo biosensor + app (Lingo Count adaptive metric, personalized recommendations, Lingo Challenges; 14-day biosensor; entry $54 / 2-week plan; Lingo Live = human nutritionist sessions)](https://www.hellolingo.com/) _Canonical: https://deploy.report/models/abbott-lingo_